Browsing by Author Yang, James Chic-Hsin

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 4 of 4
Issue DateTitleAuthor(s)Citation
2015Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trialsBoyer, Michael; Bennouna, Jaafar; Feng, Jifeng; Geater, Sarayut; Gorbunova, Vera; Hirsh, Vera; Hu, Cheng-Ping; Huang, Yunchao; Kato, Terufumi; Lee, Ki Hyeong; Lee, Kye Young; Lu, Shun; Massey, Dan; Mok, Tony; O'Byrne, Kenneth; Orlov, Sergey; Popat, Sanjay; Schuler, Martin; Sebastian, Martin; Sequist, Lecia; Shahidi, Mehdi; Su, Wu-Chou; Tsai, Chun-Ming; Wu, Yi-long; Yamamoto, Nobuyuki; Yang, James Chic-Hsin; Zazulina, Victoria; Zhou, Caicun; Central Clinical School: MedicineAfatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials, Lancet Oncology, vol.16, 2, 2015,pp 141-151
2016Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trialBoyer, Michael; et al, Various; Hirsh, Vera; Lee, Ki Hyeong; Lu, Shun; Mok, Tony; O'Byrne, Ken J; Park, Keunchil; Tan, Eng Huat; Yang, James Chic-Hsin; Zhang, Li; Central Clinical School: MedicineAfatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial, The Lancet Oncology, vol.17, 5, 2016,pp 577-589
2017Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trialBoyer, Michael; et al, Various; Hirsh, Vera; Lee, Ki Hyeong; Lu, Shun; Mok, Tony; O'Byrne, Kenneth J.; Paz-Ares, Luis; Tan, Eng Huat; Yang, James Chic-Hsin; Zhang, Li; Central Clinical School: MedicineAfatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial, Annals of Oncology, vol.28, 2, 2017,pp 270-277
2015Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-AnalysisDing, Pei Ni; Gebski, Val; Lee, Chee Khoon; Lord, Sarah (Sally); Pavlakis, Nick; Gralla, Richard J; Inoue, Akira; Links, Matthew; Mitsudomi, Tetsuya; Rosell, Rafael Costa; Wu, Yi-long; Yang, James Chic-Hsin; Zhou, Ci-Xiang; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Northern Clinical School: MedicineImpact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis, Journal of Clinical Oncology, vol.33, 17, 2015,pp 1958-1965